Loading...
 

January - March 2017: 
Volume 30, Issue 1

Click on the image to download the Issue in PDF format.

ARCHIVE

IPAF: Interstitial pneumonia with autoimmune features. A new entity?
Authors Information
1: Thoracic Medicine, University Hospital , University of Crete, Heraklion, Greece
2: Molecular and Cellular Pneumonology Laboratory, Medical School, University of Crete, Heraklion, Greece
References
  1. Ryerson CJ, Collard HR. Update on the diagnosis and classifica-tion of ILD. Curr Opin Pulm Med, 2013;19:453-9.
  2. Raghu G, et al. An Official ATS/ERS/JRS/ALAT Statement: Idi-opathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. American Journal of Respiratory and Critical Care Medicine 2011; 183:788-824.
  3. MS. Hypersensitivity pneumonitis. In: Interstitial lung disease, 5th ed, ed. a.K.T.J. Chwarz M. 2011, People’s Medical Publishing House-USA. 4. Travis, W.D., et al.
  4. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165:277-304.
  5. Fischer A, et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J 2015; 46:976-87.
  6. Fischer A, et al. Connective tissue disease-associated interstitial lung disease: a call for clarification. Chest 2010; 138:251-6.
  7. Kaunisto J, et al. Idiopathic pulmonary fibrosis - a systematic review on methodology for the collection of epidemiological data. BMC Pulmonary Medicine 2013;13:53.
  8. Karakatsani A, et al. Epidemiology of interstitial lung diseases in Greece. Respiratory Medicine 2009; 103:1122-9.
  9. Ryerson CJ, et al. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J 2013; 42:750-7.
  10. Navaratnam V, et al. Does the presence of connective tissue disease modify survival in patients with pulmonary fibrosis? Respir Med 2011; 105:1925-30.
  11. Fischer A, et al. Mycophenolate mofetil improves lung func-tion in connective tissue disease-associated interstitial lung disease. J Rheumatol 2013; 40:640-6.
  12. Corte TJ, et al. Significance of connective tissue disease fea-tures in idiopathic interstitial pneumonia. Eur Respir J 2012; 39:661-8.
  13. Park JH, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 2007; 175:705-11.
  14. Kim EJ, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2010; 35:1322-8.
  15. Vij R, Noth I, Strek ME. Autoimmune-featured interstitial lung disease: a distinct entity. Chest 2011;140:1292-9.
  16. Kinder BW, et al. Idiopathic nonspecific interstitial pneumo-nia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med 2007; 176:691-7.
  17. N, et al. Idiopathic Pulmonary Fibrosis Clinical Research. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366:1968-77.
  18. King TE, Jr, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370:2083-92.
  19. Richeldi L, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370:2071-82.
  20. Ahmad K, et al. Interstitial pneumonia with autoimmune features: Clinical, radiologic, and histological characteristics and outcome in a series of 57 patients. Respiratory Medicine 123:56-62.
  21. Oldham JM, et al. Characterisation of patients with interstitial pneumonia with autoimmune features. Eur Respir J 2016; 47:1767-75.